BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) CEO Ugur Sahin sold 37,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $99.20, for a total value of $3,670,400.00. Following the completion of the sale, the chief executive officer directly owned 744,709 shares in the company, valued at approximately $73,875,132.80. This represents a 4.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.
- On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total value of $3,520,080.00.
- On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.
- On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.
BioNTech Trading Up 0.3%
NASDAQ BNTX opened at $96.73 on Friday. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00. The stock has a market cap of $24.46 billion, a P/E ratio of -12.35 and a beta of 1.29. The stock’s fifty day moving average price is $96.98 and its 200-day moving average price is $95.38. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01.
Analyst Upgrades and Downgrades
BNTX has been the topic of a number of recent analyst reports. Morgan Stanley cut their price target on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th. BMO Capital Markets lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $128.00 to $105.00 in a report on Tuesday. Canaccord Genuity Group lowered their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. UBS Group upgraded BioNTech from a “neutral” rating to a “buy” rating and increased their target price for the company from $117.00 to $135.00 in a research note on Wednesday, May 27th. Finally, Citigroup decreased their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.
Get Our Latest Stock Analysis on BNTX
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in BNTX. Larson Financial Group LLC boosted its holdings in BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. EFG International AG purchased a new stake in BioNTech during the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of BioNTech during the 2nd quarter valued at $39,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.
BioNTech Company Profile
BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.
The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany.
Featured Articles
- Five stocks we like better than BioNTech
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
